COMMUNIQUÉS West-GlobeNewswire
-
CorTec Announces Successful Second Human Implantation of Its Brain-Computer Interface (BCI) System
10/02/2026 -
BioRestorative Completes Patient Enrollment in Landmark Phase 2 Trial of BRTX-100 for Chronic Lumbar Disc Disease
10/02/2026 -
Trinity Biotech Glucose Monitoring Innovation Achieves Unique Global Recognition: Diabetes Care Premier Hb9210™ HbA1c Analyser Becomes the Only System Awarded Prestigious IFCC Gold Classification for 2026
10/02/2026 -
Transdermal GFR Article Recognized as One of Five 2025 Editors’ Choice Articles by Journal of the American Society of Nephology (JASN)
10/02/2026 -
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
10/02/2026 -
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
10/02/2026 -
Daxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business
10/02/2026 -
Health Canada cannabis guidance exposes “absurd” education gap in healthcare
10/02/2026 -
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
10/02/2026 -
Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk
10/02/2026 -
Repligen to Report Fourth Quarter and Full Year 2025 Financial Results
10/02/2026 -
Yatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286
10/02/2026 -
Fangzhou’s MaaS Platform Recognized as Industry Leader at Guangdong Digital Economy Conference
10/02/2026 -
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
10/02/2026 -
Kainova Therapeutics Secures $32M CAD to Accelerate Development of Immuno-Oncology and Inflammation Therapies
10/02/2026 -
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
10/02/2026 -
Nicox : Présentation des données des études de Phase 3 de NCX 470 au congrès annuel 2026 de l’American Glaucoma Society (AGS)
10/02/2026 -
Santhera Appoints Stifel as Corporate Finance Advisor
10/02/2026 -
Philips delivers full year 2025 with growth acceleration, strong margin expansion and solid cash flow; announces 2026-2028 targets at Capital Markets Day
10/02/2026
Pages